Phase 1 study of the safety and tolerability of CORT125134.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2016
At a glance
- Drugs CORT 125134 (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- 28 Apr 2016 Results published in a Corcept Therapeutics media release.
- 13 Oct 2015 The results of this trial will be presented at the annual meeting of the American Association of Pharmaceutical Scientists, according to a Corcept Therapeutics media release.
- 12 Mar 2015 New trial record